Ranbaxy Laboratories (Ranbaxy) has introduced a once-a-day anti-allergic nasal spray in India. The Osonase (Ciclesonide) aqueous nasal spray is prescribed for use in treatment of seasonal and perennial allergic rhinitis in adults and adolescents.
Commenting on the launch, Sanjeev Dani, senior VP & regional director (Asia & CIS), Ranbaxy, said: “The launch of Osonase underpins our commitment to provide contemporary patient friendly solutions for the effective management of respiratory disorders like seasonal and perennial allergic rhinitis.”
“Today Ranbaxy offers a wide range of innovative products in the asthma segment with novel delivery mechanisms such as dry powder inhalers (DPIs) and pMDIs that are hydro fluoro alkane (HFA) – environment friendly propellant – technology based inhalers, and nasal sprays to suit the convenience of patients,” he added.
Allergic rhinitis represents a global health problem and is believed to be a precursor for Asthma. It is a common disease worldwide affecting at least 10-25% of the population and its prevalence is increasing. Moreover it alters the social life of the patients and affects school performance and work productivity and therefore the cost implications are substantial
A release of company stated that company has introduced the nasal spray in 50mcg strength. About 10 to 25 percent of global population is affected by allergic rhinitis, and is believed to a precursor of Asthma.